Loading data for INSM — first visit, this takes a few seconds.

Insmed (INSM)

NasdaqGS: INSM · Real-Time Price · USD

129.41

+2.13 (1.67%)

At close: Sep 11, 2026, 3:59 PM

129.41

+0.00%

After-hours: 7:56 PM

Alert

The price, the headline numbers and the latest news, in one place.

1.67% (1D)

Bid	119.59
Market Cap	28.3B
Revenue (ttm)	1.14B
Net Income (ttm)	-875M
	0.82
	-4.07
	n/a
	175.18
P/B (ttm)	37.29
P/S (ttm)	24.84
Earnings Date	Oct 29, 2026

Ask	138.39
Volume	1,698,199
Avg. Volume (20D)	3,099,319
Open	127.98
Previous Close	127.28
Day's Range	126.52 - 130.25
52-Week Range	90.39 - 212.75
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About INSM

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also de...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 1, 2000

Employees 1,664

Stock Exchange NasdaqGS

Ticker Symbol INSM

Website https://www.insmed.com

Full Company Profile

Financial Performance

In 2025, Insmed's revenue was 606.42M, an increase of 66.73% compared to the previous year's 363.71M. Earnings were -1.28B, an increase of 39.73%.

Financial Statements

Earnings Surprise

Insmed has released their quarterly earnings on Aug 6, 2026:

Revenue of $425.49M misses estimates by $0, with 296.11% YoY growth.
EPS of -0.06 exceeds estimates by 0.62, with 96.47% YoY growth.

Next Earnings Release

Insmed is scheduled to release its earnings on Oct 29, 2026, before market opens.
Analysts project revenue of ... Upgrade

Why Price Moved

News

1 week ago · Insider Monkey

Do You Believe in Insmed’s INSM) Long-Term Potential Despite Short-Term Challenges?

Artisan Partners, an investment management company, released its second-quarter 2026 investor commentary for the “Artisan Global Opportunities Strategy”. The letter can be downloaded here. Global equi...

1 week ago · Insider Monkey

Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business

On August 6, Insmed (NASDAQ:INSM) reported second-quarter results that mark a turning point for a company long defined by red ink. Total revenue hit $425.5 million, up 296% from the same quarter of 20...